Praxis Precision Medicines
PRAX
74 hedge funds and large institutions have $196M invested in Praxis Precision Medicines in 2023 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 21 increasing their positions, 20 reducing their positions, and 14 closing their positions.
45% more capital invested
Capital invested by funds: $135M → $196M (+$61M)
5% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 20
0.26% more ownership
Funds ownership: 5.68% → 5.93% (+0.26%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
5% less funds holding
Funds holding: 78 → 74 (-4)
21% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 14
Top Buyers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.04M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
+$2.84M |
| 3 |
BlackRock
New York
|
+$1.6M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.08M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$1.07M |
Top Sellers
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$4.94M |
| 2 |
ABG
Ally Bridge Group
New York
|
-$2.7M |
| 3 |
Verition Fund Management
Greenwich,
Connecticut
|
-$1.8M |
| 4 |
MS
Maven Securities
St Helier,
Jersey
|
-$1.55M |
| 5 |
Millennium Management
New York
|
-$1.34M |
PRAX Hedge Fund Activity: Q3 2023 in Review
74 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Praxis Precision Medicines (PRAX) for Q3 2023, worth a combined $196M — up 45% from $135M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of PRAX and 11 opened new positions — a net loss of 3 holders — while 20 trimmed existing stakes and 21 added.
The largest buyer was Vanguard Group, adding an estimated $4.04M. The largest seller was Sphera Funds Management, cutting an estimated $4.94M.
- 74 institutional investors held Praxis Precision Medicines (PRAX) as of Q3 2023, down from 78 in Q2 2023.
- Funds reported $196M of Praxis Precision Medicines stock for Q3 2023, up 45% quarter-over-quarter.
- 11 funds opened new Praxis Precision Medicines positions in Q3 2023 and 14 closed out, a net change of -3 holders.
- The largest Praxis Precision Medicines buyer in Q3 2023 was Vanguard Group, an estimated $4.04M added.
- The largest Praxis Precision Medicines seller in Q3 2023 was Sphera Funds Management, an estimated $4.94M sold.
Based on aggregated 13F filings for Q3 2023.